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i.org/1cardiovascular (CV) risk. Consistent with these ﬁndings, recent genetic evidence from
mutational analyses, genome-wide association studies, and Mendelian randomization
studies provide robust evidence that triglycerides and triglyceride-rich lipoproteins are in the
causal pathway for atherosclerotic CV disease, indicating that they may play a pathogenic
role, much like low-density lipoprotein cholesterol (LDL-C). Although statins are the
cornerstone of dyslipidemia management, high triglyceride levels may persist in some
patients despite statin therapy. Several triglyceride-lowering agents are available, including
ﬁbrates, niacin, and omega-3 fatty acids, of which prescription omega-3 fatty acids have the
best tolerability and safety proﬁle. In clinical studies, omega-3 fatty acids have been shown to
reduce triglyceride levels, but products containing both eicosapentaenoic acid and
docosahexaenoic acid may increase LDL-C levels. Icosapent ethyl, a high-purity eicosa-
pentaenoic acideonly product, does not raise LDL-C levels and also reduces triglyceride,
nonehigh-density lipoprotein cholesterol, and triglyceride-rich lipoprotein levels. In
conclusion, omega-3 fatty acids are currently being evaluated in large CV outcome studies in
statin-treated patients; these studies should help to elucidate the causative role of
triglycerides in atherosclerotic CV disease.  2016 The Author. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;118:138e145)Epidemiologic studies have demonstrated that elevated
triglyceride levels are independently associatedwith increased
cardiovascular (CV) risk.1 Consistent with the epidemiologic
data, clinical studies have shown that reaching target triglyc-
eride levels correlates with reduced CV risk.2 Moreover, tri-
glyceride lowering has been associated with reduced CV risk
in certain patients with high baseline triglyceride levels.2
Together, these data infer that elevated triglyceride levels are
a biomarker of CV risk. However, accumulating evidence
reviewed herein suggests that triglycerides and triglyceride-
rich lipoproteins (TRLs) are in the causal pathway of athero-
sclerotic CV disease (ASCVD), indicating that they play a
pathogenic role in atherosclerosis rather than simply serving as
a biomarker of disease risk. This studyprovides anoverviewof
TRL metabolism, describes genetic evidence supporting the
role of triglycerides and TRLs in the causal pathway of
ASCVD, and discusses the relevance of these data for man-
aging patients with dyslipidemia.
Overview of TRL Metabolism
Triglycerides are major components of TRLs, including
very-low-density lipoprotein (VLDL) and chylomicrons,
which are synthesized and secreted from the liver andBiomedical Research Institute, Harbor-University of
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0.1016/j.amjcard.2016.04.004intestinal enterocytes, respectively (Figure 1).3 Lipoprotein
lipase (LPL) promotes hydrolysis of the core triglycerides
in VLDL and chylomicrons, producing VLDL remnants
and chylomicron remnants, both of which are enriched in
cholesterol relative to triglycerides.4 Some of these parti-
cles may be taken up by the liver and cleared; those that
remain in circulation are further modiﬁed by LPL and
hepatic lipase, resulting in formation of cholesterol-
enriched LDL particles.3 In the clinical setting,
nonehigh-density lipoprotein cholesterol (noneHDL-C)
reﬂects the cholesterol content found in all potentially
atherogenic lipoproteins but principally in LDL and in the
VLDL remnants and chylomicron remnants.5 Therefore, to
calculate remnant cholesterol (the cholesterol content found
in the VLDL remnants and chylomicron remnants), the
LDL cholesterol (LDL-C) level may be simply subtracted
from the noneHDL-C level. As with LDL particles, VLDL
remnants and chylomicron remnants can be taken up by
macrophages in the arterial wall, where they may
contribute to vascular inﬂammation and atherosclerotic
plaque development and progression; however, unlike LDL
particles, remnant particles do not require oxidative
modiﬁcation for this to occur.3
Several apolipoproteins (Apos) are components of VLDL
and chylomicrons and are important in TRL metabolism.
ApoC-II is a cofactor necessary for full activation of LPL,4
whereas ApoA-V appears to enhance LPL activity, possibly
by facilitating interactions between LPL and TRLs. In
contrast, ApoC-III inhibits LPL and may also contribute to
hepatic VLDL assembly and secretion.3 The angiopoietin-
like proteins ANGPTL3 and ANGPTL4 are secreted pro-
teins that also inhibit LPL activity, potentially leading toccess article
4.0/).
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Figure 1. Schematic showing metabolism of TRLs. Factors that activate LPL lead to decreases in plasma triglyceride and TRL levels, whereas those that block
LPL lead to increases in plasma triglyceride and TRL levels. ANGPTL ¼ angiopoietin-like protein; HL ¼ hepatic lipase. Reproduced with permission from
Khetarpal and Rader, 2015.3
Review/Triglycerides in Cardiovascular Disease 139increased triglyceride levels.3,4 Importantly, genetic alter-
ations in these factors may have a substantial impact on TRL
metabolism and triglyceride levels, and in turn, on athero-
sclerotic processes and CV outcomes. In addition, recent
data from the Jackson Heart Study demonstrated that the
ApoA-I/remnant ratio was strongly associated with coronary
heart disease incidence.6
Genetic Evidence for Triglycerides and TRLs in the
Causal Pathway of ASCVD
Genetic variants in LPL and Apos involved in TRL
metabolism have been identiﬁed and allow further evalua-
tion of whether triglycerides and TRLs are involved in the
causal pathway of ASCVD (Tables 1 to 3).7e23 Genetic data
may be considered particularly compelling for evaluating
whether a lipid biomarker is causally related to disease.
Evaluation as to whether speciﬁc individual genetic loci are
causally related to disease can overcome limitations asso-
ciated with establishing causal inferences based on obser-
vational epidemiologic studies (e.g., reverse causation
arising from interrelations among LDL-C, HDL-C, and tri-
glycerides). Moreover, genetic data are not limited by con-
founding design issues that may complicate clinical studies,
such as the use of inappropriate study populations, insufﬁ-
cient magnitude of triglyceride lowering, and limited sta-
tistical power.Mutational analyses/exome sequencing: Early studies
found that mutations conferring reduced TRL metabolism are
associated with atherosclerosis and CHD, whereas those
enhancing TRL metabolism have the opposite clinical effect.
Several substitution mutations have been identiﬁed at the N-
terminal end of LPL that reduce its catalytic activity. In ameta-
analysis, carriers of the Gly188Glu substitution mutation in
LPL had reduced LPL activity, an average increase in
triglyceride levels of 78%, and a nearly ﬁvefold increased
CHD risk compared with noncarriers.24 The effects of the
Asp91Asn and Asn291Ser mutations on LPL activity and
triglyceride levels were smaller, and they had only a
borderline effect on CHD risk. Loss-of-function mutations in
ApoC-II, the activating cofactor for LPL, have been reported
to cause profound increases in serum triglyceride levels
leading to chylomicronemia and pancreatitis.25,26 Similarly,
mutations in the gene encoding ApoA-V have been
associated with increased triglyceride levels as well as
higher risk of myocardial infarction (MI)/coronary artery
disease11 and increased risk of CHD (Table 1).12
Mutations in APOC3 have the opposite effect, consistent
with the inhibitory effect of this Apo on LPL activity. In a
cohort of Amish subjects, carriers of an R19X mutation in
APOC3 had a 46% reduction in serum triglyceride levels
compared with noncarriers, which was associated with a
65% reduction in risk of coronary artery calciﬁcation, a
Table 2
Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: genome-wide association analyses
Reference N Study Type Key Results
Teslovich,
201015
96,598* Meta-analysis of 46 lipid GWAS Identiﬁed 95 loci, including regions encoding ANGPTL3 and ANGPTL4; 4 novel CAD-
associated loci related to HDL-C or TGs but not LDL-C
Schunkert
201116
147,733 Meta-analysis of 14 GWAS of CAD Identiﬁed 13 novel loci associated with 6 to 17% increase in risk of CAD; included regions
associated with increased TGs
Willer
201317
188,578 Linear regression of 149 lipid SNPs TG effect size correlated with CAD (Pearson r¼0.46; P¼0.02)
Do
201318
188,577 Multivariate analysis of 185 lipid SNPs TG effect size correlated with CHD after adjusting for LDL-C and HDL-C effect
sizes (P¼1 x 10-9)
Apo ¼ apolipoprotein; CAD ¼ coronary artery disease; CHD ¼ coronary heart disease; GWAS ¼ genome-wide association studies; HDL-C ¼ high-density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SNPs ¼ single nucleotide polymorphisms; TGs ¼ triglycerides.
* For triglycerides.
Table 3
Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: Mendelian randomization studies
Reference N Variable Effect on TGs Effect on Cardiovascular Outcome
Jorgensen
201319
60,113 10 combinations of 3 APOA5 variants Stepwise increase up to 56% MI: causal OR¼1.94 (95% CI: 1.40e1.85);
observational OR¼1.57 (95% CI: 1.32e2.68)*
Varbo
201320
73,513 3 non-fasting cholesterol-increasing alleles Correlated with remnant
cholesterol (r2¼0.96)
IHD: causal OR¼2.8 (95% CI: 1.9e4.2);
observational OR¼1.4 (95% CI: 1.3e1.5)†
Varbo
201321
60,608 6 non-fasting cholesterol-increasing alleles Not measured IHD: causal OR¼3.3 (95% CI: 2.1e5.2);
observational OR¼1.3 (95% CI: 1.2e1.4)†
Thomsen
201422
10,208 4 LPL genetic variants Stepwise decrease up to 31%z All-cause mortality: HR¼0.86 for 6 LPL alleles vs
0e3 LPL alleles (95% CI: 0.83e0.88)
Holmes
201523
62,199{ 67 triglyceride-related SNPs Mean increase of 28.5% CHDx: OR (unrestricted)¼1.62 (95% CI: 1.24e
2.11); OR (restricted)¼1.61 (95% CI: 1.00e2.59)
Apo ¼ apolipoprotein; CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; HDL-C ¼ high-density lipoprotein cholesterol; IHD ¼ ischemic heart
disease; LDL-C ¼ low-density lipoprotein cholesterol; LPL ¼ lipoprotein lipase; MI ¼ myocardial infarction; OR ¼ odds ratio; SNPs ¼ single nucleotide
polymorphisms; TGs ¼ triglycerides.
* For doubling of nonfasting triglyceride levels.
† For 1 mmol/L (39 mg/dl) increase in remnant cholesterol levels.
zWith increasing number of LPL alleles.
x Unrestricted allele scores were based on all 67 triglyceride-related SNPs; restricted allele scores were for 1-log increment in triglyceride level and included
only 27 triglyceride-related SNPs that were not also associated with LDL-C or HDL-C.
{Meta-analysis of 17 studies.
Table 1
Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: mutational analyses
Reference N Variable Effect on TGs Effect on Cardiovascular Outcome
Pollin 20087 809 ApoC-III R19X null mutation e46%
(P¼4  10-13)
CAC: OR¼0.35 (95% CI: 0.21e0.60; P¼0.002)
Jorgensen 20148 75,725 ApoC-III null mutations e44%
(P<0.001)
IVD: HR¼0.59 (95% CI: 0.41e0.86; P¼0.007)
IHD: HR¼0.64 (95% CI: 0.41e0.99; P¼0.04)
Crosby 20149 3,734 ApoC-III null mutations e39%
(P¼6  10-9)
CHD: OR¼0.60 (95% CI: 0.47e0.75; P¼4  10-6)
Natarajan 201510 6,699 ApoC-III null mutations e43.7%
(P¼1.83  10-21)
CAC: e27.9 U (95% CI: e51.1 to e4.7; P¼0.019)
Do 201511 13,432 ApoA-V mutations þ61%
(P¼0.007)
MI/CAD: OR¼2.2 (P¼5  10-7)
Sarwar 201012 302,430 ApoA-V variant þ16%
(P¼4.4  10-24)
CHD: HR¼1.10 (95% CI: 1.08e1.12; P¼2.6  10-7)
Dewey 201613 42,930 ANGPTL4 variants e13%
(P¼2x10-23)
CAD: OR¼0.81 (95% CI: 0.70e0.92; P¼0.002)
Stitziel 201614 120,575 ANGPTL4 variants e0.3 standard deviations per allele CAD: OR¼0.86 (P¼4.0  10-8)*
ANGPTL4 ¼ angiopoietin-like 4; Apo ¼ apolipoprotein; CAC ¼ coronary artery calciﬁcation; CAD ¼ coronary artery disease; CHD ¼ coronary heart
disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; IHD ¼ ischemic heart disease; IVD ¼ ischemic vascular disease; MI ¼ myocardial infarction; OR ¼
odds ratio; TGs ¼ triglycerides.
* 95% CI not reported.
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Consistent with these ﬁndings, rare loss-of-function
APOC3 mutations found through exome sequencing were
associated with decreased triglyceride levels and CHD risk
compared with noncarriers in 2 recent studies (Table 1).8,9
Similarly, a recent analysis of APOC3 mutations in sub-
jects of European, African, Asian, and Hispanic ancestries
also found that carriers had reduced plasma triglycerides and
decreased burden of coronary artery calciﬁcation
(Table 1).10
Most recently, ANGPTL4 mutations were shown to be
associated with lower triglyceride levels and lower risk of
coronary artery disease (Table 1).13,14
Genome-wide association studies: Genome-wide asso-
ciation studies are designed to search large cohorts for com-
mon genetic variants, such as single nucleotide
polymorphisms (SNPs) that occur more frequently in patients
with a certain disease comparedwith thosewithout the disease,
to identify susceptibility genes that may contribute to that
disease. Genome-wide association studies have been
conducted to identify susceptibility loci for CHD as well as
speciﬁc lipid traits that have been associated with CHD;
these studies detected susceptibility loci in gene regions
encoding ApoC-III, ApoA-V, ANGPTL3, and ANGPTL4
(Table 2).15,16 In the genome-wide association studies
evaluating lipid traits, a linear regression analysis was
performed to evaluate how lipid levels were related to CHD
risk. Notably, signiﬁcant associations with CHD risk were
found for LDL-C effect size (Pearson r ¼ 0.74; p ¼ 7 
106) and triglyceride effect size (Pearson r ¼ 0.46; p ¼
0.02) but not for HDL-C effect size (r ¼ 0.0009; p ¼
0.99).17 Because most SNPs affect multiple lipid fractions, a
multivariate analysis was performed on the 185 SNPs that
had moderate to strong effects on triglyceride levels; the
triglyceride effect size was strongly associated with CHD
after adjusting for both LDL-C and HDL-C effect sizes
(Table 2).18 Similar analyses showed that LDL-C (p ¼ 2 
1022), but not HDL-C (p ¼ 0.35), was associated with
CHD after correcting for the other corresponding lipids.
Extending our understanding of the genetic contributions
of lipid-related traits beyond the genomic studies of DNA
sequence variants, an epigenome-wide association study
examined the relation between fasting blood lipid levels and
differential methylation sites.27 In this study, methylation at
4 sites of intron 1 of carnitine palmitoyltransferase 1A was
found to be strongly associated with triglyceride and VLDL
cholesterol levels and may represent novel loci involved in
the prevention of CVD.27
Mendelian randomization studies: Mendelian random-
ization studies are based on the segregation and independent
assortment of speciﬁc genotypes according to the laws of
Mendelian genetics.28 In these studies, subjects with speciﬁc
genotypes that predispose to a speciﬁc effect (e.g.,
hypertriglyceridemia) are compared with subjects without
those genotypes. Because these studies are not affected by
confounding factors seen in observational epidemiologic
studies, they can provide robust evidence for the causal
involvement of a speciﬁc mechanism in a disease state.
Mendelian randomization studies have been conducted thatevaluate whether factors involved in TRL metabolism are
causally associated with atherosclerosis and CHD (Table 3).
Several Mendelian randomization studies were conduct-
ed using data from 3 Copenhagen population cohorts. In the
ﬁrst study, 3 common APOA5 variants were used to deﬁne
10 common genotype combinations, which were associated
with substantial stepwise increases in nonfasting triglyceride
levels and calculated remnant cholesterol levels (which is
the cholesterol content of TRLs), and with corresponding
increases in risk of MI.19 For a doubling of nonfasting tri-
glyceride levels and calculated remnant cholesterol levels,
the causal odds ratios for risk of MI were 1.94 (95% CI 1.40
to 1.85) and 2.23 (95% CI 1.48 to 3.35), respectively.
Studies 2 and 3 evaluated genotypes associated with
increasing nonfasting remnant cholesterol levels and
differed based on which APOA5 and LPL genotypes were
used to deﬁne increasing remnant cholesterol levels.20,21
Both studies found that remnant cholesterol levels were
highly correlated with nonfasting triglyceride levels and
with observed CHD risk (Table 3). A subsequent Mendelian
randomization study using data from the Copenhagen City
Heart Study found that genetic variants in LPL resulted in
reduced triglyceride levels, and that a higher number of
triglyceride-decreasing LPL alleles was associated with
increased survival (p ¼ 0.004).22
To overcome limitations inwhich only a limited number of
variants are used, a Mendelian randomization meta-analysis
was conducted using data from 17 studies involving 62,199
participants and 12,099 CHD events.23 Unrestricted allele
scoreswere determined based on all SNPs that had established
associations with triglycerides, HDL-C, or LDL-C, and then
restricted allele scores were generated in which SNPs were
excluded if they were also associated with either of the 2 other
lipids. For triglycerides, both the unrestricted allele score
based on 67 SNPs and the restricted allele score based on 27
SNPs were signiﬁcantly associated with CHD (Table 3).
Allele scores for LDL-C but not HDL-C were signiﬁcantly
associated with CHD. However, for HDL-C, the restricted
allele score was not associated with CHD; the odds ratio for a
1 mmol/L (39 mg/dl) genetic increment in HDL-C level was
0.91 (95% CI 0.42 to 1.98).
Taken together, the genetic data for triglycerides and
TRLs align with the epidemiologic and clinical data and
support a causative role for these lipids in ASCVD and
compare favorably with those linking LDL-C with ASCVD,
in contrast to those for HDL-C that did not show a causative
role in CV disease.29e31 The latter ﬁnding is notable given
that HDL-Ceincreasing drugs have failed to improve CV
outcomes in large clinical studies.32,33
Clinical implications: Statins are widely used as an
adjunct to diet and exercise in the ﬁrst-line treatment of
patients with lipid abnormalities. Statins substantially
reduce LDL-C levels and may also help to lower
triglyceride levels. However, the effects of statins on
triglyceride levels are often insufﬁcient, and therefore a
triglyceride-lowering agent may need to be added to
statin therapy if triglyceride levels remain high.
Treatment options include omega-3 fatty acids, niacin,
and ﬁbrates.
142 The American Journal of Cardiology (www.ajconline.org)Several prescription omega-3 fatty acid products are
available; each is currently approved as an adjunct to diet for
reducing triglyceride levels in adult patients with severe
hypertriglyceridemia (500 mg/dl).34 Most prescription
omega-3 fatty acid products (omega-3-acid ethyl esters
[Lovaza; GlaxoSmithKline, Research Triangle Park, North
Carolina]; omega-3-acid ethyl esters A [Omtryg; Trygg
Pharma, Arlington, Virginia]; and omega-3-carboxylic acids
[Epanova; AstraZeneca, Wilmington, Delaware]) contain a
mixture of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA).34 However, icosapent ethyl (Vascepa; Amarin
Pharma Inc., Bedminster, New Jersey) is a high-purity pre-
scription formulation containing the ethyl ester of EPA.35 In
clinical trials, all prescription omega-3 fatty acids signiﬁcantly
reduced triglyceride levels in hypertriglyceridemic patients in
the absence or presence of background statin therapy.36e45
Notably, the products containing both EPA and DHA were
found in clinical trials to increase LDL-C levels, an unwanted
potential effect in treating patients with lipid abnormalities.34
In contrast, icosapent ethyl did not increase LDL-C levels
compared with placebo in clinical trials.39,40 Icosapent ethyl,
as well as products containing both EPA and DHA, has also
shownbeneﬁcial effects on the levels of other atherogenic lipid
parameters discussed herein, including noneHDL-C, VLDL
cholesterol, and/or TRLs.37e40,42,46
Omega-3 fatty acid prescription products have well-
established favorable safety and tolerability proﬁles.34 In
contrast, niacin and ﬁbrates, although effective in reducing
triglyceride levels and other lipid parameters, are associated
with tolerability issues that may compromise treatment.
Niacin causes ﬂushing, which many patients ﬁnd intoler-
able, and also has the potential to increase serum glucose
and cause liver toxicity or myopathy, particularly when
coadministered with a statin.47 Fibrates may blunt the
beneﬁcial effects of statins on LDL-C, particularly in pa-
tients with atherogenic dyslipidemia,48 and like niacin, has
the potential to cause myopathy when used in combination
with a statin.47 The use of niacin or ﬁbrates in combination
with a statin has recently been removed from the labels of
several products because of the lack of data showing CV
beneﬁt with these combinations.
The beneﬁts of omega-3 fatty acids may extend beyond
triglyceride lowering, including effects on vascular
and cardiac hemodynamics, arrhythmia, inﬂammation,
endothelial function, thrombosis, and production of
inﬂammation-resolving mediators such as resolvins and
protectins.49 Although both EPA and DHA may contribute
to health beneﬁts of omega-3 fatty acids, it is also important
to note that EPA, as a 20-carbon fatty acid, but not DHA (a
22-carbon fatty acid), can displace arachidonic acid (also a
20-carbon fatty acid) in metabolic pathways and thus
antagonize arachidonic-mediated inﬂammatory reactions.50
Indeed, EPA speciﬁcally has been shown to have pleio-
tropic effects that beneﬁcially inﬂuence multiple steps in
atherosclerosis development and progression including
endothelial dysfunction, oxidative stress, foam cell forma-
tion, inﬂammation and cytokine effects, plaque formation
and progression, platelet aggregation, thrombus formation,
and plaque rupture.51
Recent studies support the concept that add-on therapy
to a statin can reduce residual risk and provide CVbeneﬁt.52e55 Two large outcome trials are testing the
triglyceride-lowering hypothesis with prescription omega-3
fatty acid products in statin-treated patients at high CV
risk. The Reduction of Cardiovascular Events with EPA-
Intervention Trial (REDUCE-IT; NCT01492361) is evalu-
ating 4 g/day icosapent ethyl (prescription EPA only),
whereas the Statin Residual Risk Reduction With Epanova
in High CV Risk Patients With Hypertriglyceridemia study
(STRENGTH; NCT02104817) is evaluating omega-3-
carboxylic acids (prescription EPA plus DHA). The pri-
mary end point is a composite including CV death, MI,
stroke, revascularization, and hospitalization for unstable
angina. Data from these clinical outcome trials will help to
elucidate whether high-dose prescription omega-3 fatty acid
products reduce ASCVD in high-risk, statin-treated patients,
such as those commonly encountered in clinical practice.Acknowledgment: Medical review, scientiﬁc reference
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